Table 1.

Patient demographics and epitope specificities of individuals tested for anti-proteinase 3 (PR3) humoral epitopes.

						Epitope
Patient number	Age	Ancestry	Sex	c-ANCA	PR3 units	1	2	3	4	5	6	7
1	64	EA	M	540	16	++	+++	−	++	−	−	−
2	39	NA	F	20	16	++	++	+	++	++	+	+
3	47	EA	F	540	129	+++	+++	+	+++	+	+++	+
4	53	EA	M	540	106	−	−	−	−	−	+	−
5	49	EA	F	540	231	++	+++	+	++	+	−	++
6	65	Other	M	540	80	+	+	+	++	+	+	+
7	54	EA	M	60	133	+++	+++	+++	++	+	++	+
8	30	EA	M	180	29	−	−	−	+	+	−	+
9	61	Unknown	M	180	69	+	+	+	++	++	+	++
10	27	EA	M	180	43	++	+	++	++	+	+	+

Targeting of epitopes by each patient in terms of standard deviations (s.d.) above the normal average binding. The binding of each epitope is defined by a scale where (−) represents binding < 3 s.d. above PR3-negative control responses, (+) represents binding between 3 s.d. and 5 s.d. above controls, (++) binding between 5 s.d. and 7 s.d. and (+++) binding > 7 s.d. EA: European American; NA: Native American; C-ANCA: cytoplasmic anti-neutrophil antibodies.